The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 203 KB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Tidsskrift | British Journal of Dermatology |
Vol/bind | 187 |
Udgave nummer | 2 |
Sider (fra-til) | 274-274 |
ISSN | 0007-0963 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
Ingen data tilgængelig
ID: 313866645